Profile
Sildigra 250 is a medication primarily known for its vasodilatory effects. It belongs to a class of drugs called phosphodiesterase type 5 (PDE5) inhibitors, commonly used to treat erectile dysfunction and pulmonary hypertension. In the context of neurovascular coupling, Sildigra 250 Mg inhibits the breakdown of cyclic guanosine monophosphate (cGMP), a signaling molecule that promotes vasodilation. Alzheimer's disease (AD) remains a formidable challenge in neurology, characterized by progressive cognitive decline and memory loss. At the heart of AD pathology lies neurovascular coupling (NVC), a critical mechanism that ensures adequate blood supply to the brain regions involved in cognitive function. When NVC is impaired, as seen in AD, neurons may not receive sufficient oxygen and nutrients, exacerbating cognitive deficits.